繁體版 / 簡體版
 
R&D PORTFOLIO
/ OB-318

OB-318

Indication
New Anti-cancer Drug
Mechanism
Mechanism of Action: Composite mechanism of action effectively inhibit the growth, metastasis, and angiogenesis of tumor.
Status
USFDA and TFDA approved phase I clinical trials.
Product Advantages
1.Efficacy: significantly inhibit the growth of tumor in allogenic subcutaneous xenograft model or refractory orthotopic xenograft model of maliligant cancers.
2.Safety: The concentration ratio that inhibit cancer cells and normal cells reaches 100 times, with optimal selectively.
3.Quality: standard quality control procedures to effectively control active ingredients from the fermentation of raw materials to final products.
4.Exclusiveness: Antrodia cinnamomea is an endemic species of Taiwan, with related research and development leading the world. Foreign competitors can hardly have access to the raw materials.
Potential Market
The market for anti-liver cancer drugs was about 24.5 billion US dollars in 2014. It is expected to grow to 33.8 billion US dollars in 2019.
  • The OB318 is according the ICH guideline and USFDA published standards to execut the pre-clinical research. All the technologies and quality are followed the international standards. Multiple cancer cell lines and normal cell line were used to evaluate the anticancer activity and safety range. The anticancer activity of OB318 was also verified by different animal models of diseases.


好玩棋牌 江南高纤股票分析 贵州省快3走势图 江西11选5是官方开奖吗 湖北十一选五爱彩乐开奖结果 新疆11选5中奖助手 3u娱乐成百家乐 甘肃快3走走势图爱彩乐 北京11选五开奖结果走势图 幸运农场有什么规律 安徽快3遗漏数据一牛